Prognostic utility of tumor grade and IDH-mutation status for immunotherapy response in high grade glioma: a systematic review and meta-analysis.
Srivats Srinivasan, Mohammad Mirahmadi Eraghi, Peace Odiase et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the prognostic value of tumor grade and IDH-mutation status in high-grade gliomas treated with immunotherapy. It included 21 studies with 207 patients having grade III gliomas and 11 studies with 115 IDH-mutant gliomas. Newly diagnosed IDH-mutant gliomas showed significantly better overall survival (43.13 months) compared to recurrent IDH-mutant gliomas (19.57 months, p=0.005).
Key findings
- Overall survival for recurrent and newly diagnosed grade III gliomas was not significantly different (21.90 vs 29.71 months, p=0.237).
- Newly diagnosed IDH-mutant gliomas had significantly lower 5-year mortality compared to recurrent cases (10.26% vs 59.78%, p<0.001).
- Dendritic cell and peptide vaccines improved overall survival in IDH-mutant gliomas compared to other immunotherapy agents (p=0.002).
Why it matters
Understanding the impact of tumor grade and IDH status on immunotherapy outcomes can guide treatment decisions and patient counseling in high-grade glioma management. This study highlights the need for tailored approaches based on tumor characteristics.
What to keep in mind
The study is limited by the predominance of single-arm studies and small sample sizes, which may confound the results.